Pegcetacoplan Continues to Reduce Geographic Atrophy Lesion Growth: 18-Month Data
DERBY and OAKS are phase 3, multicenter, randomized, double-masked, sham-controlled studies.
DERBY and OAKS are phase 3, multicenter, randomized, double-masked, sham-controlled studies.
Faricimab noninferior to aflibercept for visual acuity gains in neovascular age-related macular degeneration, diabetic macular edema
Review the January 2022 notable drug approvals.
Vabysmo is a humanized bispecific antibody that works by inhibiting the angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) pathways.
This slideshow shows drug information for Susvimo. Click here for the complete Susvimo monograph.
Susvimo delivers ranibizumab via ocular implant, which is surgically inserted into the eye during a one-time, outpatient procedure and refilled every 6 months.
The BLA submission is based on positive results across four phase 3 studies in wet AMD and DME.
February is AMD and Low Vision Awareness Month. There are several modifications patients can make to their lifestyles that may help reduce their risk of AMD.